FOLLOW US

The Ascend $791M Fund has closed above expectations, signaling fresh momentum in healthcare private equity as Ascend Capital Partners announced Wednesday it secured $791 million in capital commitments for its second fund.

Advised by Kirkland & Ellis LLP, the healthcare-focused investment firm surpassed its initial $700 million target, underscoring strong investor appetite for its strategy.

Fund II Outpaces Its Predecessor

The new vehicle, Ascend Capital Partners Fund II LP, not only beat its goal but also eclipsed the firm’s inaugural fund, which closed at its $570 million hard cap in December 2021 and has since been fully deployed across eight investments.

The second fund is aimed squarely at physician and provider services, value-based care enablement platforms and healthcare information technology companies. Ascend said it will continue working alongside physicians, clinical leaders and management teams to build scalable healthcare platforms designed to enhance clinical quality and foster sustainable growth.

A Strategy Focused on Care and Scale

Managing Partner Richard Park said the firm’s mission extends beyond financial returns.

“We invest in and support efforts designed to strengthen healthcare quality, expand access, and improve patient outcomes,” Park said. He added that Ascend’s operating expertise and in-house resources allow it to collaborate closely with physicians and executives to improve clinical performance, bolster compliance and documentation integrity, and build platforms positioned for long-term impact.

The fund has already begun deploying capital, backing companies including Seoul Medical Group and Unison Therapy Services, according to the firm’s statement.

Broad Investor Backing

Ascend Capital Partners Fund II drew support from a wide range of both new and returning limited partners. The investor base includes public and private pension funds, foundations, endowments, consultants, family offices and funds of funds — a cross-section of institutional capital signaling confidence in the firm’s healthcare thesis.

Managing Partner In Seon Hwang thanked investors for their backing, calling it a reflection of trust in the firm’s mission and performance.

“We look forward to building on our momentum and remain focused on partnering closely with physicians and management teams to build stronger healthcare organizations that improve patient outcomes while generating durable, long-term value,” Hwang said.

Full details regarding the Kirkland legal team advising Ascend were not immediately available Wednesday.

With nearly $800 million in fresh capital, Ascend’s latest fund positions the firm to deepen its footprint in a healthcare sector increasingly defined by value-based models, technology integration and the pursuit of measurable outcomes.